Sanctuary Advisors LLC Takes $945,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY

Sanctuary Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,139 shares of the biopharmaceutical company’s stock, valued at approximately $945,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the last quarter. Coldstream Capital Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 2.4% during the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 38 shares during the period. Atlantic Union Bankshares Corp boosted its stake in shares of Alnylam Pharmaceuticals by 20.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 40 shares during the period. Finally, Laird Norton Wetherby Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 3.3% during the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 40 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ALNY shares. Needham & Company LLC reduced their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Oppenheimer cut their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Chardan Capital reissued a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Finally, Citigroup cut their price objective on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $386.14.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $236.56 on Friday. The firm has a market cap of $31.65 billion, a PE ratio of 43.97 and a beta of 0.30. The firm’s 50 day simple moving average is $263.44 and its 200-day simple moving average is $294.13. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the business earned ($0.51) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.